利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.028 秒)

    Dibenz�b,e!oxepin derivatives and pharmaceutical agents which contain them
    1.
    发明授权
    Dibenz�b,e!oxepin derivatives and pharmaceutical agents which contain them 失效
    二苯并[b，e] oxepin衍生物和含有它们的药剂

    公开(公告)号：US5696155A

    公开(公告)日：1997-12-09

    申请号：US632473

    申请日：1996-09-10

    申请人： Walter-Gunar Friebe ,  Werner Scheuer ,  Ulrich Tibes

    发明人： Walter-Gunar Friebe ,  Werner Scheuer ,  Ulrich Tibes

    IPC分类号： A61K31/335 ,  C07D313/12 ,  C07D493/04

    CPC分类号： C07D493/04 ,  C07D313/12

    摘要： Compounds of formula I ##STR1## in which Q denotes hydrogen, a hydroxy group or a C.sub.1 to C.sub.8 alkoxy group which can be substituted if desired, by carboxyl or C.sub.1 to C.sub.6 alkoxycarbonyl and either Y and Z together form a group ##STR2## and X represents hydrogen, C.sub.1 to C.sub.6 alkyl or C.sub.2 to C.sub.6 alkenyl or Y and X together form a group ##STR3## or an alkylene residue of 2-4 carbon atoms and Z represents hydrogen, C.sub.1 to C.sub.6 alkyl or C.sub.1 to C.sub.6 alkanoyl, where R denotes hydrogen or a C.sub.1 to C.sub.6 alkyl residue as well as physiologically tolerated salts thereof, processes for their production and pharmaceutical agents containing these compounds for the treatment of inflammatory diseases and allergic diseases.

    摘要翻译： PCT No.PCT / EP94 / 03479 371日期：1996年9月10日 102（e）1996年9月10日PCT PCT日期：1994年10月22日PCT公布。 公开号WO95 / 11906 日期：1995年5月4日，式I的化合物（I）其中Q表示氢，羟基或可根据需要被取代的C 1至C 8烷氧基，由羧基或C 1至C 6烷氧基羰基以及Y和Z一起 形成基团，X表示氢，C 1至C 6烷基或C 2至C 6烯基或Y和X一起形成基团Z表示氢，C 1至C 6烷基或C 1至C 6烷酰基，其中R表示氢或 C1至C6烷基残基以及其生理上耐受的盐，其制备方法和含有这些化合物用于治疗炎症性疾病和过敏性疾病的药剂。

    Benzotriazines, pharmaceutical compositions, and methods of using same
    2.
    发明授权
    Benzotriazines, pharmaceutical compositions, and methods of using same 失效
    苯并三嗪，药物组合物及其使用方法

    公开(公告)号：US5856325A

    公开(公告)日：1999-01-05

    申请号：US464631

    申请日：1995-06-26

    申请人： Walter-Gunar Friebe ,  Werner Scheuer ,  Ulrich Tibes

    发明人： Walter-Gunar Friebe ,  Werner Scheuer ,  Ulrich Tibes

    IPC分类号： C07D253/08 ,  A61K31/53 ,  A61P29/00 ,  A61P37/08 ,  C07D251/08 ,  C07D253/10

    CPC分类号： C07D253/10 ,  A61K31/53

    摘要： Use of compounds of the formula I ##STR1## in which R.sub.1 signifies an amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or a hydroxyl group, R.sub.2 and R.sub.3, which are the same or different, each hydrogen, halogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, cyano, carboxyl, halogen-C.sub.1 -C.sub.6 -alkyl, cyano-C.sub.1 -C.sub.6 -alkyl, carboxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 - alkyl, hydroxyl, carboxy-C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxycarbonyl-C.sub.1 -C.sub.6 -alkoxy or aminocarbonyl-C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylaminocarbonyl-C.sub.1 -C.sub.6 -alkoxy or di-C.sub.1 -C.sub.6 -alkylaminocarbonyl-C.sub.1 -C.sub.6 -alkoxy and n the number 0 or 1, their tautomers, as well as salts with non-toxic acids or bases, for the preparation of medicaments with PLA.sub.2 -inhibiting action, new compounds and process for their preparation.

    摘要翻译： PCT No.PCT / EP93 / 03542 Sec。 371日期：1995年6月26日 102（e）日期1995年6月26日PCT提交1993年12月15日PCT公布。 公开号WO94 / 14781 日期：1994年7月7日使用下式的化合物，其中每个氢，卤素，C 1 -C 6 - 烷基，其相同或不同的氨基，二-C 1 -C 6烷基氨基或羟基，R 2和R 3， ，C 1 -C 6 - 烷氧基，氰基，羧基，卤素-C 1 -C 6烷基，氰基-C 1 -C 6烷基，羧基-C 1 -C 6烷基，C 1 -C 6烷基，羟基，羧基-C 1 -C 6 - 烷氧基 C 1 -C 6烷氧基羰基-C 1 -C 6烷氧基或氨基羰基-C 1 -C 6烷氧基，C 1 -C 6烷基氨基羰基-C 1 -C 6烷氧基或二-C 1 -C 6烷基氨基羰基-C 1 -C 6烷氧基， 0或1，它们的互变异构体，以及与无毒酸或碱的盐，用于制备具有PLA2抑制作用的药物，新化合物及其制备方法。

    Pyrazolo(3,4-d)pyrimidine compounds, compositions and method of use
    9.
    发明授权
    Pyrazolo(3,4-d)pyrimidine compounds, compositions and method of use 失效
    吡唑并（3,4-d）嘧啶化合物，组合物和使用方法

    公开(公告)号：US4904666A

    公开(公告)日：1990-02-27

    申请号：US181729

    申请日：1988-04-14

    申请人： Walter-Gunar Friebe ,  Wolfgang Kampe ,  Otto-Henning Wilhelms

    发明人： Walter-Gunar Friebe ,  Wolfgang Kampe ,  Otto-Henning Wilhelms

    IPC分类号： A61K31/505 ,  A61K31/519 ,  A61P11/08 ,  A61P11/16 ,  A61P29/00 ,  A61P37/08 ,  C07D487/04

    CPC分类号： C07D487/04

    摘要： The present invention provides pyrazolo[3,4-d]-pyrimidines of the general formula: ##STR1## wherein R.sub.1 is a C.sub.1 to C.sub.6 -alkyl radical, a C.sub.2 to C.sub.6 -alkenyl radical, a C.sub.3 to C.sub.7 -cycloalkyl radical or an aryl radical, R.sub.2 is a C.sub.2 to C.sub.6 -alkenyl radical, a C.sub.3 to C.sub.7 -cycloalkyl radical or an aralkyl or hetaralkyl radical with 1 to 6 carbon atoms in the alkyl moiety and substituted, if desired, one or more times by halogen, C.sub.1 to C.sub.6 -alkyl, hydroxyl, C.sub.1 to C.sub.6 -alkoxy, C.sub.1 to C.sub.3 -haloalkyl, C.sub.3 to C.sub.7 -alkoxy carbonyl, aminocarbonyl, C.sub.2 to C.sub.7 -alkylaminocarbonyl, C.sub.3 to C.sub.13 -dialkylaminocarbonyl, cyano or C.sub.1 to C.sub.6 -alkylthio and R.sub.3 is a hydrogen atom or a C.sub.2 to C.sub.6 -alkyl radical substituted, if desired, one or more times by hydroxyl or is a tetrahydrofuranyl or tetrahydropyranyl radical, with the proviso that R.sub.2 cannot be an unsubstituted benzyl radical when R.sub.1 is a methyl radical, and the physiologically acceptable salts thereof with inorganic and organic acids.The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

    摘要翻译： 本发明提供通式如下的吡唑并[3,4-d] - 嘧啶：其中R 1为C 1至C 6 - 烷基，C 2至C 6链烯基，C 3至C 7环烷基 基团或芳基，R 2是C 2至C 6 - 烯基，C 3至C 7 - 环烷基或在烷基部分具有1至6个碳原子的芳烷基或杂烷基，如果需要， 卤素，C1至C6烷基，羟基，C1至C6烷氧基，C1至C3-卤代烷基，C3至C7-烷氧基羰基，氨基羰基，C2至C7-烷基氨基羰基，C3至C13-二烷基氨基羰基，氰基或C1至C6-烷硫基 并且R 3是氢原子或C 2至C 6烷基如果需要，被羟基取代一次或多次，或者是四氢呋喃基或四氢吡喃基，条件是当R 1是甲基时，R 2不能是未被取代的苄基 ，以及其与无机和有机酸的生理上可接受的盐。 本发明还提供了制备这些化合物的方法和含有它们的药物组合物。

    N.sup.6 -disubstituted purine derivatives, and pharmaceutical compositions containing them, useful for treating allergic diseases, bronchospastic and bronchoconstrictory conditions
    10.
    发明授权
    N.sup.6 -disubstituted purine derivatives, and pharmaceutical compositions containing them, useful for treating allergic diseases, bronchospastic and bronchoconstrictory conditions 失效
    N6-二取代嘌呤衍生物和含有它们的药物组合物，其可用于治疗过敏性疾病，支气管痉挛和支气管收缩条件

    公开(公告)号：US4853386A

    公开(公告)日：1989-08-01

    申请号：US897109

    申请日：1986-08-15

    申请人： Walter-Gunar Friebe ,  Otto-Henning Wilhelms

    发明人： Walter-Gunar Friebe ,  Otto-Henning Wilhelms

    IPC分类号： A61K31/52 ,  A61P11/08 ,  A61P37/08 ,  C07D473/00 ,  C07D473/16 ,  C07D473/34 ,  C07D473/40

    CPC分类号： C07D473/00 ,  C07D473/16 ,  C07D473/34

    摘要： The present invention provides N.sup.6 -disubstituted purine derivatives of the general formula: ##STR1## wherein R.sub.1 and R.sub.4 are the same or different and each represents a hydrogen or halogen atom or an --NR.sub.6 R.sub.7 group, R.sub.2 and R.sub.3 are the same or different and each represents a C.sub.1 -C.sub.6 alkyl radical, a C.sub.2 -C.sub.6 alkenyl radical, a C.sub.3 -C.sub.7 cycloalkyl radical, a phenalkyl radical containing up to 4 carbon atoms in the alkyl moiety, which can be straight-chained or branched, the phenyl moiety of which can be substituted one or more times by halogen, hydroxyl, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio or trifluoromethyl; a furylmethyl or furylethyl radical, a thiophenemethyl or thiopheneethyl radical, a pyridylmethyl or pyridylethyl radical optionally substituted by a C.sub.1 -C.sub.4 alkyl radical, an indanyl radical or a tetrahydronaphthyl radical, R.sub.5 is a hydrogen atom, a tetrahydrofuranyl or tetrahydropyranyl radical or a C.sub.1 -C.sub.10 radical which is optionally substituted one or more times by hydroxyl, C.sub.1 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.6 alkoxycarbonyl, C.sub.2 -C.sub.6 carboxyalkanoyloxy, C.sub.2 -C.sub.6 hydroxyalkoxy, C.sub.3 -c.sub.6 dihydroxyalkoxy, carboxyl, cyano or 1H-tetrazol-5-yl radical, R.sub.6 and R.sub.7 are the same or different and each represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl radical or together represent a C.sub.2 -C.sub.5 alkylene radical optionally interrupted by oxygen, sulphur or an NR.sub.8 group and R.sub.8 is a hydrogen atom or a C.sub.1 -C.sub.6 alkyl radical; as well as the pharmacologically acceptable salts thereof.

    摘要翻译： 本发明提供以下通式的N6-二取代的嘌呤衍生物：其中R 1和R 4相同或不同，并且各自表示氢或卤素原子或-NR 6 R 7基团，R 2和R 3相同或不同， 各自表示C1-C6烷基，C2-C6链烯基，C3-C7环烷基，在烷基部分含有至多4个碳原子的苯烷基，其可以是直链或支链的，苯基 其部分可以被卤素，羟基，C 1 -C 6烷基，C 1 -C 6烷氧基，C 1 -C 6烷硫基或三氟甲基取代一次或多次; 呋喃基甲基或呋喃乙基，噻吩甲基或噻吩乙基，任选被C 1 -C 4烷基，茚满基或四氢萘基取代的吡啶基甲基或吡啶基，R5是氢原子，四氢呋喃基或四氢吡喃基或C1- C 1 -C 6烷氧基，C 1 -C 6烷氧基羰基，C 2 -C 6羧基烷酰氧基，C 2 -C 6羟基烷氧基，C 3 -C 6二羟基烷氧基，羧基，氰基或1H-四唑-5-基 ，R6和R7相同或不同，各自表示氢原子或C1-C6烷基，或一起代表任选被氧，硫或NR8基中断的C2-C5亚烷基，R8是氢原子或C1 -C6烷基; 以及其药理学上可接受的盐。